SYNCOMF

Syncom Formulation (India) Share Price

 

 

Start SIP in SYNCOMF

Start SIP

Performance

  • Low
  • ₹14
  • High
  • ₹15
  • 52 Week Low
  • ₹14
  • 52 Week High
  • ₹23
  • Open Price₹15
  • Previous Close₹15
  • Volume1,477,427

Investment Returns

  • Over 1 Month -7.17%
  • Over 3 Month -14.56%
  • Over 6 Month -25.33%
  • Over 1 Year -27.86%

Smart Investing Starts Here Start SIP with Syncom Formulation (India) for Steady Growth!

Invest Now

Syncom Formulation (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.6
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 1,363
  • P/B Ratio
  • 3.6
  • Average True Range
  • 0.46
  • EPS
  • 0.67
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.37
  • RSI
  • 33
  • MFI
  • 38.37

Syncom Formulation (India) Financials

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹14.50
-0.18 (-1.23%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹14.99
  • 50 Day
  • ₹15.65
  • 100 Day
  • ₹16.38
  • 200 Day
  • ₹17.02

Resistance and Support

14.5 Pivot Speed
  • R3 14.89
  • R2 14.78
  • R1 14.61
  • S1 14.33
  • S2 14.22
  • S3 14.05

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Syncom Formulations Ltd. manufactures pharmaceutical products, including tablets, capsules, syrups, and ointments. Serving both domestic and international markets, it offers a broad range of affordable, high-quality medicines across therapeutic segments like antibiotics, pain relief, and vitamins.

Syncom Formulations India has an operating revenue of Rs. 515.03 Cr. on a trailing 12-month basis. An annual revenue growth of 74% is outstanding, Pre-tax margin of 14% is healthy, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Syncom Formulation (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-08 Quarterly Results & A.G.M.
2025-05-19 Audited Results
2025-02-10 Quarterly Results & Others To consider other business matters. alia, 1. To consider and allot upto 15,93,47,820 Warrants of Rs. 2.53 convertible into equity shares of Rs. 1/- each at a premium of Rs. 1.53 per share for every warrant of the company.
2024-11-11 Quarterly Results

Syncom Formulation (India) F&O

Syncom Formulation (India) Shareholding Pattern

50.57%
0%
0.1%
45.21%
4.12%

About Syncom Formulation (India)

  • NSE Symbol
  • SYNCOMF
  • BSE Symbol
  • 524470
  • Managing Director
  • Mr. Vijay Shankarlal Bankda
  • ISIN
  • INE312C01025

Similar Stocks to Syncom Formulation (India)

Syncom Formulation (India) FAQs

Syncom Formulation (India) share price is ₹14 As on 26 December, 2025 | 22:46

The Market Cap of Syncom Formulation (India) is ₹1363 Cr As on 26 December, 2025 | 22:46

The P/E ratio of Syncom Formulation (India) is 21.6 As on 26 December, 2025 | 22:46

The PB ratio of Syncom Formulation (India) is 3.6 As on 26 December, 2025 | 22:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23